News

BrainStorm Cell Therapeutics Faces Major Setback with Nasdaq Dispute

BrainStorm Cell Therapeutics Faces Major Setback with Nasdaq Dispute

BrainStorm Cell Therapeutics Faces Major Setback

BrainStorm Cell Therapeutics Inc. (BCLI) shares plummeted by 42.74% to $0.67 in after-hours trading on Friday following the company's announcement of its voluntary delisting from the Nasdaq Capital Market. This significant drop has raised concerns among investors and the larger biotechnology community.

The Delisting Announcement

BrainStorm officially announced it received a formal notification from The Nasdaq Stock Market LLC indicating that its common stock would be suspended from trading at market open on Friday. The delisting is mainly due to the company's failure to comply with the Nasdaq Listing Rule 5550(b)(1), which stipulates that companies must maintain a minimum amount of shareholder equity.

Year-to-Date Performance

Year-to-date, BrainStorm's stock has witnessed a decline of approximately 45.33%. The stock closed at $1.17 on Thursday prior to the after-hours selloff, reflecting the downward trend this year. Following the delisting, the company has gained approval to trade on the OTCQB Venture Market, utilizing the same BCLI ticker symbol effective immediately.

CEO's Assurance to Stakeholders

In a statement, CEO Chaim Lebovits reassured shareholders and the patient community saying, “While this delisting from Nasdaq is a challenging outcome, we want to assure our shareholders and the patient community that it does not alter our core mission.” BrainStorm expressed its ongoing commitment to developing its lead investigational therapy, NurOwn, which targets amyotrophic lateral sclerosis (ALS).

Continued Focus on ALS Treatment

BrainStorm's operations and research endeavors remain intact despite the delisting, reinforcing the company's commitment to its innovative treatments. The proprietary NurOwn platform employs autologous adult stem cells to produce neurotrophic factor-secreting cells designed specifically for ALS patients. This therapy holds Orphan Drug designation from both the FDA and the European Medicines Agency, highlighting its potential therapeutic value.

Planned Clinical Trials

Moving forward, BrainStorm completed a Phase 3 ALS trial and plans to initiate a Phase 3b trial under a Special Protocol Assessment agreement with the FDA. Additionally, the company has undertaken a Phase 2 trial for progressive multiple sclerosis, backed by a grant from the National MS Society.

Market Impact and Investment Opportunities

Market analysts view the recent events as pivotal for BrainStorm. Despite the setback, the company's short-term price trend remains positive according to recent evaluations. Investors are advised to remain vigilant regarding future developments and the company's plans moving forward.

Frequently Asked Questions

What caused BrainStorm's stock to drop significantly?

The stock dropped significantly due to the announcement of its voluntary delisting from the Nasdaq Capital Market following non-compliance with specific listing rules.

What is the core mission of BrainStorm Cell Therapeutics?

BrainStorm is focused on developing therapies for neurodegenerative diseases, particularly through its lead investigational therapy for ALS known as NurOwn.

Where can BrainStorm shares be traded after the delisting?

Following the delisting from Nasdaq, BrainStorm shares are now trading on the OTCQB Venture Market under the same BCLI ticker symbol.

What does the CEO say about the company's future?

CEO Chaim Lebovits stated that the core mission of the company remains unchanged despite the delisting, ensuring continued dedication to ALS treatment.

What regulatory designations has NurOwn received?

NurOwn has received Orphan Drug designation from both the FDA and the European Medicines Agency, indicating its significant potential for patients with ALS.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

MedStar's Same-Day Test Puts Stroke Drugs on Notice

Updated Category News Views 40

A five-hour lab result can matter more than another glossy precision-medicine slogan. MedStar Health says it is using same-day genetic testing for patients with ischemic stroke, giving clinicians information before discharge that previously often arrived more than a week later. That is a practical change, not science-fiction wallpaper: a treatment decision gets made while...

Continue Reading
Stowers Brings a Transformation CTO Into Its Lab

Updated Category News Views 0

Data Has Become Lab Infrastructure Microscopes may get the glory, but the plumbing behind modern biology is increasingly digital, sprawling and unforgiving. That is why Stowers Institute for Medical Research appointing Brandon Mayer as vice president and chief technology officer on November 19, 2026, deserves more attention than the usual executive-shuffle treatment. This...

Continue Reading
Compounded Peptides Demand Clearer FDA Status Answers

Updated Category News Views 73

Peptide talk has gotten muddled enough to make plain English feel revolutionary. The central point in the HelloNation article featuring wellness expert Andres Giraldo is straightforward: a compounded peptide is not FDA approved in the same product-specific manner as a commercially manufactured drug. That is not a small semantic wrinkle, and it should not be buried beneath...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 117

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading
Century Lithium Clears a Crucial Nevada Permit Gate

Updated Category News Views 65

Permitting news rarely rings a cash register, but it can stop one from being bolted shut. Century Lithium has received confirmation from the Bureau of Land Management’s Tonopah Field Office that baseline studies for its wholly owned Angel Island lithium project in Esmeralda County, Nevada, are complete. The agency also set the project on the Environmental Impact...

Continue Reading
RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 138

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 143

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
IDEMIA Lands Sweden's Critical 5G Connectivity Job

Updated Category News Views 85

A hospital monitor going dark because a device was misprovisioned is not the kind of connectivity hiccup anybody gets to shrug off. That is why IDEMIA Secure Transactions winning the Region Västra Götaland assignment deserves more attention than the usual telecom plumbing announcement. The region is building what it calls Sweden's largest private 5G network, and the job...

Continue Reading
Accredited Debt Relief Earns Personalized Honor in 2026

Updated Category News Views 45

A High Score Is Useful, Not a Free Pass Debt relief rankings can get awfully shiny when a company has a good week, but this one has some actual detail behind it. USA Today named Accredited Debt Relief its best provider for personalized debt relief in its 2026 review, handing the company a 94 out of 100. The ranking was published November 11 and updated November 12, and...

Continue Reading
Qiandaohu Whisky Film Puts Craft Before Market Hype

Updated Category News Views 59

Three Distillers, One Very Large Question Whisky does not become world-class because a camera crew found a pretty shoreline. That is the blunt truth sitting underneath this Nov. 19, 2026 documentary release from CCTV+. The film follows three international distillers working at three separate whisky distilleries along Qiandaohu, while also lingering on their day-to-day...

Continue Reading

Top 5 Most Recently Viewed Articles

A&K Robotics Strengthens Leadership with Melonee Wise's Expertise

Updated Category News Views 289

Leadership Expansion at A&K Robotics A&K Robotics, a frontrunner in the autonomous micromobility sector, is excited to welcome Melonee Wise to its Board of Advisors. With over twenty years of rich experience in developing robotic technologies, Wise is poised to offer invaluable insights as the company continues to grow its influence worldwide. Advancing Mobility Through...

Continue Reading
Lavior Welcomes Ryan Shilling as New VP of Sales for U.S.

Updated Category News Views 147

Lavior Welcomes Ryan Shilling as New VP of Sales for U.S. Healthcare Expertise to Drive Growth and Patient-Centered Innovation Lavior, an innovator in advanced healing solutions, proudly announces the appointment of Ryan Shilling as Vice President of Sales for the U.S. market. With over 15 years of leadership experience in various healthcare sectors, Shilling is set to...

Continue Reading
Tesla's Cybertruck Delivery Plans Set to Launch in Canada

Updated Category News Views 372

Tesla Gears Up for Cybertruck Deliveries in Canada Tesla Inc. (NASDAQ: TSLA) is approaching an exciting milestone as it plans to start delivering its much-anticipated Cybertruck in Canada shortly. Recent updates on social media suggest that the event could happen as early as next week, thrilling prospective owners. Exciting Customer Announcements On social media platform...

Continue Reading
Borregaard ASA Announces Ex-Dividend Trading Notification

Updated Category News Views 191

Borregaard ASA Ex-Dividend Trading Insights Today marks the beginning of a new trading phase for Borregaard ASA as its shares are now officially traded ex-dividend at NOK 4.25 per share. This means that investors purchasing shares at this point will not receive the forthcoming dividend, which can influence buying decisions in the market. Understanding Ex-Dividend Dates...

Continue Reading
Key Legal Notice for Charter Communications' Shareholders

Updated Category News Views 189

Current Updates on Charter Communications, Inc. Charter Communications, Inc. (NASDAQ: CHTR) has been generating significant attention as it faces an ongoing class action lawsuit regarding securities fraud. This legal proceeding serves to remind shareholders of their rights and the timelines that are critical for participation. With the stakes involved, it is vital for...

Continue Reading